Correction to: Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
Dermatol Ther (Heidelb)
.
2020 Oct;10(5):1001.
doi: 10.1007/s13555-020-00422-7.
Authors
Sekwon Jang
1
,
Tayla Poretta
2
,
Tarun Bhagnani
3
,
Qing Harshaw
3
,
Matthew Burke
2
,
Sumati Rao
2
Affiliations
1
Melanoma and Cutaneous Oncology Therapeutics, Inova Schar Cancer Institute, Fairfax, VA, USA. Sekwon.Jang@inova.org.
2
Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA.
3
Health Economics and Outcomes Research, EPI-Q Inc., Oakbrook, IL, USA.
PMID:
32683664
PMCID:
PMC7477051
DOI:
10.1007/s13555-020-00422-7
Abstract
The presentation of the numbers of patients in Tables 1 and 3 was adjusted.
Publication types
Published Erratum